Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Paxos releases June PYUSD transparency report: Total circulation rises to over 499 million US dollars

Paxos releases June PYUSD transparency report: Total circulation rises to over 499 million US dollars

Bitget2024/07/23 03:57
Paxos officially released the PYUSD transparency report for June 2024, disclosing relevant unaudited data as of 06:00 on June 29, 2024 Beijing time, including:
 
1. The total circulation (Total Tokens Outstanding) reached $499,487,564;
 
2. The current market value of collateral in U.S. Treasury bonds is approximately $49,550,900 and the nominal position value is about $49,337,950;
 
3. The current market value of collateral in reverse repurchase agreements with U.S. Treasury bonds is approximately $450,447,300 and the nominal position value is about $441,615,000;
 
4. The current market value of cash deposits is approximately $10,204663 and the nominal position value is about $10,,204663;
 
5. The current market value of collateral in total net assets is approximately $510,,202863 and the nominal position value is about $$501157613.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.

Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.

智通财经2026/08/29 03:22
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.